Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury

Neuroscience Bulletin

Volumn 27, Issue 4, 2011, Pages 275-285

  Alonso Alconada, Daniel ^a   Alvarez, Antonia ^a   Hilario, Enrique ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Brain injury; Endocannabinoid system; Neuroprotective strategies; Perinatal hypoxia ischemia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ANANDAMIDE; CYCLOOXYGENASE 2; DEXANABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTAMIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPROTEIN LIPASE; LIPOXYGENASE; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CATALYSIS; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HYPOXIC ISCHEMIC ENCEPHALOPATHY; IMMUNOMODULATION; NERVE CELL; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PERINATAL ASPHYXIA; POSTNATAL DEVELOPMENT; PRENATAL DEVELOPMENT; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN; NEUROPROTECTIVE AGENTS; SYNAPTIC TRANSMISSION;

EID: 80755125651     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-011-1008-6     Document Type: Review

References (150)

1. Berger R, Garnier Y. Perinatal brain injury. J Perinat Med 2000, 28: 261-285.
2. Volpe J. Perinatal brain injury: from pathogenesis to neuroprotection. Mental Retard Dev Disabil Res 2001, 7: 56-64. (Pubitemid 32206303)
3. Low JA. Determining the contribution of asphyxia to brain damage in the neonate. J Obstet Gynaecol Res 2004, 30: 276-286. (Pubitemid 39108441)
4. Vannuci S, Hagberg H. Hypoxia-ischemia in the immature brain. J Exp Biol 2004, 207: 3149-3154. (Pubitemid 39275289)
5. de Hann M, Wyatt JS, Roth S, Vargha-Khadem F, Gadian D, Mishki M. Brain and cognitive-behavioural development after asphyxia at term birth. Dev Sci 2006, 9: 350-358. (Pubitemid 43855814)
6. Torfs CP, van den Berg B, Oechsli FW, Cummins S. Prenatal and perinatal factors in the etiology of cerebral palsy. J Pediatr 1990, 116: 615-619. (Pubitemid 20124162)
7. Mañeru C, Junque C, Botet F, Tallada M, Guardia J. Neuropsychological long-term sequelae of perinatal asphyxia. Brain Int 2001, 15: 1029-1039. (Pubitemid 33120961)
8. Yager JY, Armstrong EA, Black AM. Treatment of the term newborn with brain injury: simplicity as the mother of invention. Pediatr Neurol 2009, 40: 237-243.
9. Rivkin MJ. Hypoxic-ischemic brain injury in the term newborn: neuropathology, clinical aspects, and neuroimaging. Clin Perinatol 1997, 24: 607-626.
10. Volpe JJ. Hypoxic-ischemic encephalopathy. Clinical aspects. In: Volpe JJ (ed). Neurology of the Newborn. Philadelphia: WB Saunders Co, 1995: 314-369.
11. Nakaruma Y, Okureda T, Hashimoto T. Vascular architecture in white matter of neonates: its relationship to periventricular leukomalacia. J Neuropathol Exp Neurol 1994, 53: 582-589. (Pubitemid 24333017)
12. Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol 1998, 5: 135-151. (Pubitemid 28432520)
13. Pourcyrous M. Cerebral hemodynamic measurements in acute versus chronic asphyxia. Clin Perinatol 1999, 26: 811-828. (Pubitemid 29522286)
14. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide with the development window of vulnerability for human perinatal white matter injury. J Neurosci 2001, 21: 1302-1312. (Pubitemid 32128775)
15. Hilario E, Rey-Santano MC, Goñi-de-Cerio F, Alvarez FJ, Gastiasoro E, Mielgo VE, et al. Cerebral blood flow and morphological changes after hypoxic-ischaemic injury in preterm lambs. Acta Paediatr 2005, 94: 903-911. (Pubitemid 41044775)
16. Shalak LF, Laptook AR, Velaphi SC, Perlman JM. Amplitude-integrated electroencephalography coupled with an early neurologic examination enhances prediction of term infants at risk for persistent encephalopathy. Pediatrics 2003, 111: 351-357. (Pubitemid 36177156)
17. Sanders RD, Manning HJ, Robertson NJ, Ma D, Edwards AD, Hagberg H, et al. Preconditioning and postinsult therapies for perinatal hypoxic-ischemic injury at term. Anesthesiology 2010, 113: 233-249.
18. Perlman JM, Risser R. Can asphyxiated infants at risk for neonatal seizures be rapidly identified by current high-risk markers? Pediatrics 1996, 97: 456-462. (Pubitemid 26098291)
19. Walton M, Connor B, Lawlor P, Young D, Sirimanne E, Gluckman P, et al. Neuronal death and survival in two models of hypoxic- ischemic brain damage. Brain Res Rev 1999, 29: 137-168. (Pubitemid 29191337)
20. Ferriero DM. Neonatal brain injury. N Engl J Med 2004, 351: 1985-1995.
21. Sugawara T, Fujimura M, Noshita N, Kim GW, Saito A, Hayashi T, et al. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 2004, 1: 17-25. (Pubitemid 46589339)
22. Edwards AD, Yue X, Cox P, Hope PL, Azzopardi DV, Squier MV, et al. Apoptosis in the brains of infants suffering intrauterine cerebral injury. Pediatr Res 1997, 42: 684-689. (Pubitemid 27459479)
23. Yue X, Mehmet H, Penrice J, Cooper C, Cady EB, Wyatt JS, et al. Apoptosis and necrosis in the newborn piglet brain following transient HI. Neuropathol Appl Neurobiol 1997, 23: 16-25. (Pubitemid 27081213)
24. Esteve JM, Mompo J, García de la Asunción J, Satre J, Asensi M, Boix J, et al. Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis studies in vivo and in vitro. FASEB J 1999, 13: 1055-1064. (Pubitemid 29249731)
25. Taylor DL, Edwards AD, Mehmet H. Oxidative metabolism, apoptosis and perinatal brain injury. Brain Pathol 1999, 9: 93-117. (Pubitemid 29056522)
26. Ohyu J, Endo A, Itoh M, Takashima S. Hypocapnia under hypotension induces apoptotic neuronal cell death in the hippocampus of newborn rabbits. Pediatric Res 2000, 48: 24-29. (Pubitemid 30419167)
27. Hilario E, Alvarez A, Alvarez FJ, Gastiasoro E, Valls-i-Soler A. Cellular mechanisms in perinatal hypoxic-ischemic brain injury. Current Pediatr Rev 2006, 2: 131-141. (Pubitemid 44027840)
28. Hilario E, Cañavate ML, Lacalle J, Alonso-Alconada D, Lara- Celador I, Alvarez-Granda L, et al. Cell death. A comprehensive approximation. Delayed cell death. In: Méndez-Vilas A, Díaz J (eds). Microscopy: Science, Technology, Applications and Education. Badajoz: Formatex Research Centre, 2010: 1025-1032.
29. Gunn AJ, Gunn T, de Haan H, Williams C, Gluckman P. Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal sheep. J Clin Invest 1997, 99: 248-256. (Pubitemid 27053465)
30. Gonzalez FF, Ferriero DM. Therapeutics for neonatal brain injury. Pharmacol Ther 2008, 120: 43-53.
31. Kelen D, Robertson NJ. Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev 2010, 86: 369-377.
32. Cilio MR, Ferriero DM. Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med 2010, 15: 293-298.
33. Nedelcu J, Klein MA, Aguzzi A, Martin E. Resuscitative hypothermia protects the neonatal rat brain from hypoxic-ischemic injury. Brain Pathol 2000, 10: 61-71. (Pubitemid 30056394)
34. Pabello NG, Tracy SJ, Keller RW Jr. Protective effects of brief intra- and delayed postischemic hypothermia in a transient focal ischemia model in the neonatal rat. Brain Res 2004, 995: 29-38. (Pubitemid 37486012)
35. den Hertog H, van der Worp B, van Gemert M, Dippel D. Therapeutic hypothermia in acute ischemic stroke. Expert Rev Neurother 2007, 7: 155-164. (Pubitemid 46434165)
36. Adachi M, Sohma O, Tsuneishi S, Takada S, Nakamura H. Combination effect of systemic hypothermia and cascase inhibitor administration against hypoxic-ischemic brain damage in neonatal rats. Pediatric Res 2001, 50: 590-595. (Pubitemid 33009983)
37. Hashimoto T, Yonetani M, Nakamura H. Selective brain hypothermia protects against hypoxic-ischemic injury in newborn rats by reducing hydroxyl radical production. Kobe J Med Sci 2003, 49: 83-91. (Pubitemid 38477602)
38. Zhu C, Wang X, Cheng X, Qui L, Xu F, Simbruner G, et al. Postischemic hypothermia-induced tissue protection and diminished apoptosis after neonatal cerebral hypoxia-ischemia. Brain Res 2004, 996: 67-75. (Pubitemid 37510295)
39. Wyatt JS, Gluckman PD, Liu PY, Azzopardi D, Ballard R, Edwards AD, et al. Determinants of outcomes after head cooling for neonatal encephalopathy. Pediatrics 2007, 119: 912-921. (Pubitemid 46715661)
40. Palmer C, Towfighi J, Roberts RL, Heitjan DF. Allopurinol administered after inducing damage with HI reduces brain injury in 7 days old rats. Pediatr Res 1993, 33: 405-411. (Pubitemid 23095775)
41. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998, 101: 185-193. (Pubitemid 28076649)
42. Ferrari G, Yan CYI, Greene LA. Acetylcysteine (D- and L- sterioisomers) prevent apoptotic death of neuronal cells. J Neurosci 1995, 15: 2857-2866.
43. Yan CYI, Ferrari G, Greene LA. N-Acetylcysteine promoted survival of PC12 cells is glutathione independent but transcription dependent. J Biol Chem 1995, 270: 26827-26832.
44. Jatana M, Singh I, Singh AK, Jenkins D. Combination of systemic hypothermia and N-acetylcysteine attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2006, 59: 684-689. (Pubitemid 43740011)
45. Lee TF, Jantzie LL, Todd KG, Cheung PY. Postresuscitation Nacetylcysteine treatment reduces cerebral hydrogen peroxide in the hypoxic piglet brain. Inten Care Med 2008, 34: 190-197.
46. Sola A, Wen TC, Hamrick SE, Ferriero DM. Potential for protection and repair following injury to the developing brain: a role for erythropoietin. Pediatr Res 2005, 57: 110-117.
47. Chang YS, Mu D, Wendland M, Sheldon RA, Vexler ZS, McQuillen PS, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005, 58: 106-111. (Pubitemid 40967438)
48. Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007, 29: 321-330. (Pubitemid 47343686)
49. Carloni S, Perrone S, Buonocore G, Longini M, Proietti F, Balduini W. Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. J Pineal Res 2008, 44: 157-164. (Pubitemid 351252918)
50. Signorini C, Ciccoli L, Leoncini S, Carloni S, Perrone S, Comporti M, et al. Free iron, total F-isoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. J Pineal Res 2009, 46: 148-154.
51. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM. Minocycline markedly protects the neonatal brain against hypoxicischemic injury. Ann Neurol 2002, 52: 54-61. (Pubitemid 34693743)
52. Jantzie LL, Cheung PY, Todd KG. Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. J Cereb Blood Flow Metab 2005, 25: 314-325.
53. Carloni S, Mazzoni E, Cimino M, De Simoni MG, Perego C, Scopa C, et al. Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat. Neurobiol Dis 2006, 21: 119-126. (Pubitemid 41817312)
54. Carloni S, Girelli S, Buonocore G, Longini M, Balduini W. Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Exp Neurol 2009, 220: 82-89.
55. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4: 873-884. (Pubitemid 37351427)
56. Di Marzo V, Bisogno T, De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007, 14: 741-756. (Pubitemid 47081420)
57. Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108: 1687-1707. (Pubitemid 351796405)
58. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 247: 345-358. (Pubitemid 39298276)
59. Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, et al. Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist. J Biol Chem 2002, 277: 23278-23286. (Pubitemid 34952156)
60. Craib SJ, Ellington HC, Pertwee RG, Ross RA. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 2001, 134: 30-37. (Pubitemid 32835465)
61. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232: 54-61.
62. Núñez E, Benito C, Pazos MR, Barbachano A, Fajardo O, González S, et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004, 53: 208-213. (Pubitemid 39045539)
63. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310: 329-332. (Pubitemid 41457202)
64. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006, 1074: 514-536. (Pubitemid 44532857)
65. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071: 10-23. (Pubitemid 43255471)
66. Dewey WL. Cannabinoid Pharmacology. Pharmacol Rev 1986, 38: 151-178. (Pubitemid 16001329)
67. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54: 161-202. (Pubitemid 34575709)
68. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258: 1946-1949. (Pubitemid 23026736)
69. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50: 83-90.
70. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215: 89-97.
71. Mackie K. Mechanisms of CB1 receptor signalling: endocannabinoid modulation of synaptic strength. Int J Obesity 2006, 30: 19-23.
72. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 2001, 98: 3662-3665. (Pubitemid 32249827)
73. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301: 1020-1024. (Pubitemid 34595094)
74. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, 3: 817-824.
75. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002, 99: 8400-8405. (Pubitemid 34651064)
76. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Martinez S, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350: 240-244. (Pubitemid 24268029)
77. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998, 284: 644-650. (Pubitemid 28086654)
78. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34: 605-613. (Pubitemid 19007296)
79. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrman JL. Antinociceptive (aminoalkyl)-indoles. J Med Chem 1991, 34: 1099-1110.
80. Jansen EM, Haycock DA, Ward SJ, Seybold VS. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 1992, 575: 93-102.
81. Kuster JE, Stevenson JI, Ward SJ, D'Ambra TE, Haycock DA. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther 1993, 264: 1352-1363. (Pubitemid 23318632)
82. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372: 686-691.
83. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004, 61: 149-160. (Pubitemid 39287775)
84. Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 2002, 68-69: 521-534. (Pubitemid 35247418)
85. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 2001, 276: 35552-35557.
86. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 2005, 62: 708-716.
87. Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002, 66: 211-220. (Pubitemid 34743596)
88. Saario SM, Savinainen JR, Laitinen JT, Järvinen T, Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 2004, 67: 1381-1387. (Pubitemid 38324545)
89. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 2004, 66: 1260-1264. (Pubitemid 39411065)
90. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 2000, 108: 211-220.
91. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000, 23: 14-20. (Pubitemid 30100308)
92. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernández-Ruiz JJ. Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999, 33: 181-191. (Pubitemid 29372845)
93. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil L, Hernández ML, Ramos JA, et al. Atypical localization of cannabinoid receptors in white matter areas during rat brain development. Synapse 1997, 26: 317-323. (Pubitemid 27240747)
94. Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 2001, 14: 1463-1468. (Pubitemid 33124194)
95. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003, 17: 1747-1754. (Pubitemid 36645324)
96. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002, 296: 678-682.
97. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29: 729-738. (Pubitemid 32323945)
98. Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci 2006, 1083: 270-305. (Pubitemid 44955478)
99. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998, 21: 521-528. (Pubitemid 28555694)
100. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001, 31: 463-475. (Pubitemid 32778564)
101. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008, 14: 2279-2288.
102. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001, 85: 468-471. (Pubitemid 32062158)
103. Galante M, Diana MA. Group I metabotropic glutamate receptors inhibit GABA release atinterneuron-Purkinje cell synapses through endocannabinoid production. J Neurosci 2004, 24: 4865-4874. (Pubitemid 38668211)
104. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU, et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006, 26: 5794-5799. (Pubitemid 44315272)
105. Nemeth B, Ledent C, Freund TF, Hajos N. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2. Neuropharmacology 2008, 54: 51-57. (Pubitemid 350299414)
106. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-d-aspartate or nitric oxide? superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995, 92: 7162-7166.
107. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999, 19: 4544-4558. (Pubitemid 29241104)
108. Hajos N, Katona I, Naiem SS, Mackie K, Ledent C, Mody I, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000, 12: 3239-3249.
109. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. FEBS J 2009, 276: 2-12.
110. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/ GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007, 102: 1105-1114. (Pubitemid 47174245)
111. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signalling. Physiol Rev 2003, 83: 1017-1066. (Pubitemid 36828930)
112. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58: 389-462. (Pubitemid 44394908)
113. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004, 141: 775-785. (Pubitemid 38446178)
114. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5: 400-411. (Pubitemid 40685989)
115. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000, 899: 274-282. (Pubitemid 30352793)
116. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999, 19: 2987-2995. (Pubitemid 29173995)
117. Louw DF, Yang FW, Sutherland GR. The effect of delta-9- tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000, 857: 183-187. (Pubitemid 30107804)
118. Braida D, Pozzi M, Sala M. CP 55,940 protects against ischemiainduced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci Lett 2000, 296: 69-72.
119. Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E. Neuroprotective and brain edema reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 2003, 989: 99-111. (Pubitemid 37281406)
120. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU- 210. Stroke 2003, 34: 2000-2006. (Pubitemid 36944797)
121. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H, et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 2004, 15: 2381-2385. (Pubitemid 39488924)
122. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002, 22: 9771-9775. (Pubitemid 35332860)
123. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 2001, 21: 8765-8771. (Pubitemid 33054840)
124. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 2006, 22: 257-264.
125. Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 2008, 1240: 213-220.
126. Melis M, Pillolla G, Bisogno T, Minassi A, Petrosino S, Perra S, et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol Dis 2006, 24: 15-27. (Pubitemid 44416209)
127. Zani A, Braida D, Capurro V, Sala M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol 2007, 152: 1301-1311. (Pubitemid 350242443)
128. Degn M, Lambertsen KL, Petersen G, Meldgaard M, Artmann A, Clausen BH, et al. Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 2007, 103: 1907-1916. (Pubitemid 350126623)
129. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999, 288: 1357-1366. (Pubitemid 29254178)
130. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000, 225: 1-8.
131. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001, 24: 29-51.
132. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002, 8: 58-61. (Pubitemid 34094440)
133. Fernandez-Lopez D, Martinez-Orgado J, Nuñez E, Romero J, Lorenzo P, Moro MA, et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006, 60: 169-173. (Pubitemid 44297587)
134. Martinez-Orgado J, Fernandez-Lopez D, Lizasoain I, Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Pat CNS Drug Discov 2007, 2: 131-139. (Pubitemid 46952450)
135. Alonso-Alconada D, Alvarez FJ, Alvarez A, Mielgo VE, Goñi-de- Cerio F, Rey-Santano MC, et al. The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxicischemic injury in fetal lambs. Brain Res 2010, 1362: 150-159.
136. Gazzolo D, Vinesi P, Bartocci M, Geloso MC, Bonacci W, Serra G, et al. Elevated S100 blood levels as an early indicator of intraventricular haemorrhage in preterm infants. Correlation with cerebral Doppler velocimetry. J Neurol Sci 1999, 170: 32-35. (Pubitemid 29502532)
137. Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L. Brainspecific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr 2001, 90: 1171-1175. (Pubitemid 32964494)
138. Böttiger BW, Möbes S, Glätzer R, Bauer H, Gries A, Bärtsch P, et al. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation 2001, 103: 2694-2698. (Pubitemid 32538784)
139. Thorngren-Jerneck K, Alling C, Herbst A, Amer-Wahlin I, Marsal K. S100 protein in serum as a prognostic marker for cerebral injury in term newborn infants with hypoxic ischemic encephalopathy. Pediatr Res 2004, 55: 406-412. (Pubitemid 38240817)
140. Goñi-de-Cerio F, Alvarez A, Alvarez FJ, Rey-Santano MC, Alonso- Alconada D, Mielgo VE, et al. MgSO4 treatment preserves the ischemia-induced reduction in S-100 protein without modification of the expression of endothelial tight junction molecules. Histol Histopathol 2009, 24: 1129-1138.
141. Fernández-López D, Pazos MR, Tolón RM, Moro MA, Romero J, Lizasoain I, et al. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr Res 2007, 62: 255-260. (Pubitemid 47301471)
142. Fernández-López D, Pradillo JM, García- Yébenes I, Martínez- Orgado JA, Moro MA, Lizasoain I. The cannabinoid WIN55212-2 promotes neural repair after neonatal hypoxia-ischemia. Stroke 2010, 41: 2956-2964.
143. Fernández-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007, 28: 39-45. (Pubitemid 46038536)
144. Ashton JC, Rahman RMA, Nair SM, Sutherland BA, Glass M, Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoide CB2 receptor in the brain. Neurosci Lett 2007, 412: 114-117. (Pubitemid 46074356)
145. Mauler F, Horvath E, De Vry J, Jager R, Schwarz T, Sandmann S, et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 2003, 9: 343-358. (Pubitemid 38031863)
146. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. WIN 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/ endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004, 10: 158-164. (Pubitemid 38499908)
147. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25: 1904-1913. (Pubitemid 40289395)
148. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005, 95: 437-445. (Pubitemid 41457512)
149. Fernández-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008, 286: 91-96.
150. Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez- Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010, 37: 434-440.